Argenica Therapeutics (ASX:AGN) plans to go ahead with a “pragmatic and feasible” phase 2b trial of its stroke prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback